Responses

Dear Gloucestershire Health and Care NHS Foundation Trust,

I am writing under the Freedom of Information Act 2000 to request the following information held by your Trust.

For each of the calendar years 2022, 2023, 2024 and 2025 (to date, if full-year data is not yet available), please provide:

1. The total number of admissions to Specialist Eating Disorder Inpatient Services.
2. The total number of admissions to Intensive Day-Patient Eating Disorder Services.
Where possible, please:

• Provide the data broken down by year.
• Provide a separate figure for patients admitted with a primary diagnosis of Anorexia Nervosa.

If diagnostic breakdowns are recorded using ICD-10 or ICD-11 codes, please include the codes used to define Anorexia Nervosa.

If a breakdown by diagnosis is not readily available within the cost limit, please provide the aggregate totals only.

If the Trust does not hold some or all of this information, please confirm this and direct me to the appropriate body where possible.

I would prefer to receive the information in electronic format (Excel or CSV).

Yours faithfully,

Good evening,

I hope this email finds you well.

Please could I request the following information under the Freedom of Information Act:

1. The number of inpatients in your Trust who died in each year since 2015.
2. The number of these inpatients who were under the age of 18.

Please could you provide this information by email, preferably in a spreadsheet.

If it is not possible to provide the information requested due to the information exceeding the cost of compliance limits identified in Section 12, please provide advice and assistance, under Section 16 obligations of the Act, as to how I can refine my request.

Many thanks and best wishes,

Dear FOI team for Gloucestershire Health and Care NHS Foundation Trust,

Where possible, I would be grateful if the requested data could be provided in an editable format (e.g. .xlsx or .csv). If this is not feasible, a table format would also be acceptable, and example layouts are suggested below for reference.

For all questions, patient numbers should represent unique patients within the specified reporting period. Where a monthly breakdown is not available, please provide unique patient numbers aggregated by quarter instead. If the tables below are not showing correctly due to formatting issues, then please let me know and I can send them in a word document.

Priority questions:

1. The number of patients under the trust’s care with a recorded diagnosis of Dravet syndrome in each month of 2025 (January–December). Patients may be counted in more than one month. Likely coded as ICD-10 code G40.3 or SNOMED code 230437002.
a. Patient numbers segmented by age:
i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ 2. The number of patients under the trust’s care with a recorded diagnosis of Lennox-Gastaut syndrome in each month of 2025 (January-December). Patients may be counted in more than one month. Likely coded as ICD-10 code G40.4 or SNOMED code of 230418006. a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ Example table for Q1 & 2: Age/Month Jan-25 Feb-25 Mar-25 Apr-25 May-25 Jun-25 Jul-25 Aug-25 Sep-25 Oct-25 Nov-25 Dec-25 <2 years old 2-8 years old 9-17 years old 18+ years old 3. The number of patients under the trust’s care who have been treated with fenfluramine in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 Example table for 3 – 12 a)i – b)ii Age group / Month Jan-25 Feb-25 Mar-25 Apr-25 May-25 Jun-25 Jul-25 Aug-25 Sep-25 Oct-25 Nov-25 Dec-25 <2 years Total patients Dravet syndrome Lennox–Gastaut syndrome 2-8 years Total patients Dravet syndrome Lennox–Gastaut syndrome 9-17 years Total patients Dravet syndrome Lennox–Gastaut syndrome 18+ years Total patients Dravet syndrome Lennox–Gastaut syndrome c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 4. The number of patients under the trust’s care who have been treated with cannabidiol in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 5. The number of patients under the trust’s care who have been treated with cenobamate in in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 6. The number of patients under the trust’s care who have been treated with rufinamide in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 7. The number of patients under the trust’s care who have been treated with stiripentol in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. Good to know questions: 8. The number of patients under the trust’s care who have been treated with clobazam in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 9. The number of patients under the trust’s care who have been treated with sodium valproate in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 10. The number of patients under the trust’s care who have been treated with topiramate in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Dravet Syndrome (ICD10 Code: G40.3) SCTID: 230437002 ii. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Dravet syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication d. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. 11. The number of patients under the trust’s care who have been treated with lamotrigine in 2025 (January-December), separated by month a. Patient numbers segmented by age: i. <2 years old ii. 2-8 years old iii. 9-17 years old iv. 18 years+ b. For these patients, how many of them had a diagnosis of: i. Lennox-Gastaut syndrome (ICD10 Code: G40.4) SCTID: 230418006 c. For patients with a recorded diagnosis of Lennox–Gastaut syndrome treated with fenfluramine during 2025, please indicate which other anti-seizure medications were recorded for these patients during the year, and the number of patients associated with each medication. Many thanks,